AMLX stock icon

Amylyx Pharmaceuticals
AMLX

$2.16
6.14%
 

About: Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.

Employees: 384

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 13 analysts
0
News positive %
of 6 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

94% more call options, than puts

Call options by funds: $20.5M | Put options by funds: $10.6M

17% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 48

17.17% less ownership

Funds ownership: 90.22% [Q4 2023] → 73.06% (-17.17%) [Q1 2024]

20% less funds holding

Funds holding: 177 [Q4 2023] → 142 (-35) [Q1 2024]

58% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 60

84% less capital invested

Capital invested by funds: $897M [Q4 2023] → $141M (-$755M) [Q1 2024]

100% less funds holding in top 10

Funds holding in top 10: 4 [Q4 2023] → 0 (-4) [Q1 2024]

Research analyst outlook

13 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$3
39%
upside
Avg. target
$8.15
277%
upside
High target
$32
1,381%
upside

13 analyst ratings

positive
62%
neutral
38%
negative
0%
Goldman Sachs
Chris Shibutani
85%upside
$4
Neutral
Maintained
12 Jul 2024
HC Wainwright & Co.
Andrew Fein
270%upside
$8
Buy
Reiterated
10 Jul 2024
HC Wainwright & Co.
Andrew Fein
270%upside
$8
Buy
Reiterated
24 Jun 2024
Mizuho
Graig Suvannavejh
39%upside
$3
Neutral
Maintained
14 May 2024
HC Wainwright & Co.
Andrew Fein
270%upside
$8
Buy
Reiterated
10 May 2024

Financial journalist opinion

Based on 6 articles about AMLX published over the past 30 days